Company intelligence / Profile preview

Orion Biotechnology

Ottawa, Ontario, Canadaorionbiotechopportunities.com ↗

Ownership: Private
Development stage: Other

Overview

Orion Biotechnology is a clinical-stage biotech developing next-generation therapeutics targeting previously undruggable small protein GPCRs for obesity and metabolic disorders. The company leverages its proprietary PROcisionXTM platform to rapidly discover and develop peptide/protein-based drugs. It has a strong and diverse pipeline across development stages, though specific clinical results are not detailed in the available sources.

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: PeptidesProteinsSmall molecule
Industry: Biotech

Partnerships

Open to R&D collaborations and outlicensing opportunities centered around their PROcisionXTM platform; no specific partners named.

Beyond the preview

Go deeper on Orion Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orion Biotechnology.

Explore the full profile